

Sharon L Walmsley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4291504/publications.pdf>

Version: 2024-02-01

264
papers

13,313
citations

41344

49
h-index

24982

109
g-index

267
all docs

267
docs citations

267
times ranked

12361
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2801.	7.4	1,188
2	Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America. <i>New England Journal of Medicine</i> , 2003, 348, 2175-2185.	27.0	884
3	Antiretroviral Treatment of Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 555.	7.4	846
4	Dolutegravir plus Abacavir+Lamivudine for the Treatment of HIV-1 Infection. <i>New England Journal of Medicine</i> , 2013, 369, 1807-1818.	27.0	697
5	Lopinavir+Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection. <i>New England Journal of Medicine</i> , 2002, 346, 2039-2046.	27.0	635
6	A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis. <i>New England Journal of Medicine</i> , 2002, 346, 1119-1126.	27.0	381
7	Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. <i>Lancet, The</i> , 2011, 378, 238-246.	13.7	361
8	Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. <i>Lancet, The</i> , 2006, 368, 466-475.	13.7	326
9	A Comparison of Two Regimens for the Treatment of Mycobacterium avium Complex Bacteremia in AIDS: Rifabutin, Ethambutol, and Clarithromycin versus Rifampin, Ethambutol, Clofazimine, and Ciprofloxacin. <i>New England Journal of Medicine</i> , 1996, 335, 377-384.	27.0	304
10	Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study. <i>Journal of Infectious Diseases</i> , 2013, 207, 740-748.	4.0	271
11	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2019, 393, 143-155.	13.7	265
12	One-Year Outcomes and Health Care Utilization in Survivors of Severe Acute Respiratory Syndrome. <i>Archives of Internal Medicine</i> , 2007, 167, 1312.	3.8	244
13	Maraviroc versus Efavirenz, Both in Combination with Zidovudine+Lamivudine, for the Treatment of Antiretroviral-Naïve Subjects with CCR5-Tropic HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2010, 201, 803-813.	4.0	241
14	Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. <i>New England Journal of Medicine</i> , 2020, 382, 1124-1135.	27.0	232
15	Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. <i>Aids</i> , 1998, 12, 1653-1659.	2.2	231
16	CLINICAL UTILITY OF QUANTITATIVE CYTOMEGALOVIRUS VIRAL LOAD DETERMINATION FOR PREDICTING CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1. <i>Transplantation</i> , 1999, 68, 1305-1311.	1.0	202
17	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 515-519.	2.1	190
18	Enhanced Detection and Typing of Human Papillomavirus (HPV) DNA in Anogenital Samples with PGMY Primers and the Linear Array HPV Genotyping Test. <i>Journal of Clinical Microbiology</i> , 2006, 44, 1998-2006.	3.9	157

#	ARTICLE	IF	CITATIONS
19	Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 40, 404-412.	2.1	151
20	Invasive <i>Aspergillus</i> infections in a pediatric hospital. <i>Pediatric Infectious Disease Journal</i> , 1993, 12, 673-682.	2.0	142
21	25- TO 30-NM VIRUS PARTICLE ASSOCIATED WITH A HOSPITAL OUTBREAK OF ACUTE GASTROENTERITIS WITH EVIDENCE FOR AIRBORNE TRANSMISSION. <i>American Journal of Epidemiology</i> , 1988, 127, 1261-1271.	3.4	140
22	Fertility Desires and Intentions of HIV-Positive Women of Reproductive Age in Ontario, Canada: A Cross-Sectional Study. <i>PLoS ONE</i> , 2009, 4, e7925.	2.5	131
23	Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 50, 367-374.	2.1	108
24	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2018, 5, e211-e220.	4.7	108
25	Medicinal and Recreational Marijuana Use by Patients Infected with HIV. <i>AIDS Patient Care and STDs</i> , 2004, 18, 215-228.	2.5	101
26	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. <i>Lancet HIV</i> , 2017, 4, e536-e546.	4.7	101
27	<i>Mycobacterium xenopi</i> Infection in Patients with Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 1997, 25, 206-210.	5.8	99
28	HIV Protease Inhibitor Use During Pregnancy Is Associated With Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction. <i>Journal of Infectious Diseases</i> , 2015, 211, 10-18.	4.0	99
29	Rifabutin-Associated Uveitis. <i>Annals of Pharmacotherapy</i> , 1995, 29, 1149-1155.	1.9	97
30	Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs. <i>Clinical Infectious Diseases</i> , 2016, 62, 139-147.	5.8	97
31	Evaluation of HIV and Highly Active Antiretroviral Therapy on the Natural History of Human Papillomavirus Infection and Cervical Cytopathologic Findings in HIV-Positive and High-Risk HIV-Negative Women. <i>Journal of Infectious Diseases</i> , 2013, 208, 454-462.	4.0	96
32	Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3547.	4.3	92
33	Cohort Profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study. <i>International Journal of Epidemiology</i> , 2010, 39, 1162-1169.	1.9	91
34	Association of Age With Polypharmacy and Risk of Drug Interactions With Antiretroviral Medications in HIV-Positive Patients. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1429-1439.	1.9	90
35	Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 40, 413-421.	2.1	83
36	Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial. <i>Clinical Infectious Diseases</i> , 2006, 43, 1337-1346.	5.8	79

#	ARTICLE	IF	CITATIONS
37	Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. <i>PLoS ONE</i> , 2016, 11, e0148231.	2.5	70
38	Use of Complementary and Alternative Medicine by HIV-Infected Outpatients in Ontario, Canada. <i>AIDS Patient Care and STDs</i> , 2003, 17, 155-168.	2.5	68
39	Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients. <i>Aids</i> , 1997, 11, 1689-1697.	2.2	67
40	How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?. <i>Clinical Infectious Diseases</i> , 2016, 62, 919-926.	5.8	65
41	Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. <i>Clinical Infectious Diseases</i> , 2017, 64, 1154-1162.	5.8	64
42	Role of Drug Efflux and Uptake Transporters in Atazanavir Intestinal Permeability and Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2013, 30, 1050-1064.	3.5	62
43	Marijuana Smoking Does Not Accelerate Progression of Liver Disease in HIV/Hepatitis C Coinfection: A Longitudinal Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2013, 57, 663-670.	5.8	62
44	Caring for women living with HIV: gaps in the evidence. <i>Journal of the International AIDS Society</i> , 2013, 16, 18509.	3.0	57
45	Envisioning Women-Centered HIV Care: Perspectives from Women Living with HIV in Canada. <i>Women's Health Issues</i> , 2017, 27, 721-730.	2.0	56
46	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. <i>Lancet HIV</i> , 2020, 7, e16-e26.	4.7	53
47	A Randomized Trial of N-Acetylcysteine for Prevention of Trimethoprim-Sulfamethoxazole Hypersensitivity Reactions in Pneumocystis carinii Pneumonia Prophylaxis (CTN 057). <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 19, 498-505.	0.3	52
48	Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. <i>Cmaj</i> , 2004, 170, 47-54.	2.0	52
49	Previous Antibiotic Exposure and Antimicrobial Resistance in Invasive Pneumococcal Disease: Results From Prospective Surveillance. <i>Clinical Infectious Diseases</i> , 2014, 59, 944-952.	5.8	51
50	A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial. <i>Antiviral Therapy</i> , 2005, 10, 735-743.	1.0	51
51	A Safety Study of Oral Valganciclovir Maintenance Treatment of Cytomegalovirus Retinitis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 30, 392-400.	2.1	50
52	Mortality in HIV/Hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). <i>Aids</i> , 2014, 28, 1957-1965.	2.2	50
53	Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naïve HIV-infected individuals in three randomized trials. <i>Aids</i> , 2015, 29, 167-174.	2.2	50
54	Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS Malignancy Consortium and IM862 Study Team. <i>Journal of Clinical Oncology</i> , 2005, 23, 990-998.	1.6	49

#	ARTICLE	IF	CITATIONS
55	TORO: Ninety-Six-Week Virologic and Immunologic Response and Safety Evaluation of Enfuvirtide with an Optimized Background of Antiretrovirals. <i>AIDS Patient Care and STDs</i> , 2007, 21, 533-543.	2.5	48
56	CD36 deficiency induced by antiretroviral therapy. <i>Aids</i> , 2002, 16, 353-358.	2.2	45
57	The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol. <i>BMC Infectious Diseases</i> , 2017, 17, 611.	2.9	45
58	Confirmatory Real-Time PCR Assay for Human Papillomavirus (HPV) Type 52 Infection in Anogenital Specimens Screened for HPV Infection with the Linear Array HPV Genotyping Test. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3821-3823.	3.9	42
59	A Randomized, Placebo-Controlled Trial of Rosiglitazone for HIV-Related Lipoatrophy. <i>Journal of Infectious Diseases</i> , 2007, 195, 1754-1761.	4.0	41
60	Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-1 Phase 2 Trial. <i>Journal of Infectious Diseases</i> , 2010, 201, 590-599.	4.0	41
61	A CD4+ Cell Count <200 Cells per Cubic Millimeter at 2 Years After Initiation of Combination Antiretroviral Therapy Is Associated With Increased Mortality in HIV-Infected Individuals With Viral Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 451-459.	2.1	40
62	HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2771-2781.	3.2	38
63	Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults. <i>PLoS ONE</i> , 2011, 6, e17758.	2.5	38
64	The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. <i>Quality of Life Research</i> , 2005, 14, 981-990.	3.1	35
65	Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1. <i>Aids</i> , 2014, 28, 717-725.	2.2	35
66	Enfuvirtide (T-20) Cross-Reactive Glycoprotein 41 Antibody Does Not Impair the Efficacy or Safety of Enfuvirtide. <i>Journal of Infectious Diseases</i> , 2003, 188, 1827-1833.	4.0	34
67	Baseline HIV-1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy-Naive Patients. <i>Journal of Infectious Diseases</i> , 2004, 190, 280-284.	4.0	34
68	Self-Sampling Is Associated with Increased Detection of Human Papillomavirus DNA in the Genital Tract of HIV-Seropositive Women. <i>Clinical Infectious Diseases</i> , 2005, 41, 527-534.	5.8	34
69	Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. <i>Aids</i> , 2010, 24, 1091-1094.	2.2	34
70	HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. <i>Vaccine</i> , 2016, 34, 4799-4806.	3.8	33
71	The importance of motherhood in HIV-positive women of reproductive age in Ontario, Canada. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 777-784.	1.2	32
72	The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2019, 68, 788-794.	5.8	32

#	ARTICLE	IF	CITATIONS
73	Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials. <i>HIV Clinical Trials</i> , 2016, 17, 147-157.	2.0	31
74	Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, 363-371.	5.8	31
75	Polypharmacy in HIV: Impact of Data Source and Gender on Reported Drug Utilization. <i>AIDS Patient Care and STDs</i> , 2004, 18, 568-586.	2.5	30
76	Reproducibility of DXA Estimations of Body Fat in HIV Lipodystrophy. <i>Journal of Clinical Densitometry</i> , 2005, 8, 293-297.	1.2	29
77	A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipoatrophy. <i>HIV Clinical Trials</i> , 2010, 11, 39-50.	2.0	29
78	Ethnicity and Gender Differences in Lipodystrophy of HIV-Positive Individuals Taking Antiretroviral Therapy in Ontario, Canada. <i>HIV Clinical Trials</i> , 2011, 12, 89-103.	2.0	29
79	A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy. <i>AIDS Patient Care and STDs</i> , 2012, 26, 532-540.	2.5	29
80	Food Insecurity in HIV-Hepatitis C Virus Co-infected Individuals in Canada: The Importance of Co-morbidities. <i>AIDS and Behavior</i> , 2017, 21, 792-802.	2.7	29
81	Successful Discontinuation of Therapy for Disseminated <i>Mycobacterium avium</i> Complex Infection after Effective Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2002, 137, 734.	3.9	28
82	Protease Inhibitor-Based Regimens for HIV Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 45, S5-S13.	2.1	28
83	A Randomized Controlled Pilot Trial of Valacyclovir for Attenuating Inflammation and Immune Activation in HIV/Herpes Simplex Virus 2â€“Coinfected Adults on Suppressive Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, 1331-1338.	5.8	28
84	Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 429-440.	2.1	27
85	Once Daily Dosing Improves Adherence to Antiretroviral Therapy. <i>AIDS and Behavior</i> , 2011, 15, 1397-1409.	2.7	27
86	No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. <i>Aids</i> , 2011, 25, 207-210.	2.2	27
87	Realâ€“world impact of direct acting antiviral therapy on healthâ€“related quality of life in <sc>HIV</sc>/Hepatitis C coâ€“infected individuals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1507-1514.	2.0	26
88	Does In Vitro Susceptibility to Rifabutin and Ethambutol Predict the Response to Treatment of <i>Mycobacterium avium</i> Complex Bacteremia with Rifabutin, Ethambutol, and Clarithromycin?. <i>Clinical Infectious Diseases</i> , 1998, 27, 1401-1405.	5.8	25
89	A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 149-158.	4.7	25
90	Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study. <i>BMC Medical Research Methodology</i> , 2013, 13, 31.	3.1	25

#	ARTICLE	IF	CITATIONS
91	Low Prolactin and High 20- β -Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2016, 213, 1532-1540.	4.0	25
92	Seroprevalence and Risk Factors for Herpes Simplex Virus Infection in a Population of HIV-Infected Patients in Canada. <i>Sexually Transmitted Diseases</i> , 2009, 36, 165-169.	1.7	24
93	Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2017, 17, 246.	2.9	24
94	Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up. <i>Aids</i> , 2019, 33, 1013-1022.	2.2	23
95	The Intersection of HIV and Syphilis: Update on the Key Considerations in Testing and Management. <i>Current HIV/AIDS Reports</i> , 2021, 18, 280-288.	3.1	23
96	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1 ₂₀₀₉ and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2012, 13, 23-32.	2.0	22
97	Antiretroviral therapy is not associated with reduced herpes simplex virus shedding in HIV coinfecting adults: an observational cohort study. <i>BMJ Open</i> , 2014, 4, e004210.	1.9	22
98	Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfecting patients after hepatitis C therapy: a prospective cohort study. <i>HIV Clinical Trials</i> , 2015, 16, 100-110.	2.0	22
99	Viral suppression and viral rebound among young adults living with HIV in Canada. <i>Medicine (United States)</i> 2021; 100(10):e22107. doi:10.1093/med/100.10.e22107	1.0	22
100	SARS outbreak in the Greater Toronto Area: the emergency department experience. <i>Cmaj</i> , 2004, 171, 1342-1344.	2.0	21
101	Infectious Complications of Bio-Alcamid Filler Used for HIV-Related Facial Lipoatrophy. <i>Clinical Infectious Diseases</i> , 2012, 55, 1568-1574.	5.8	21
102	Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 503-513.	2.1	21
103	Differential predictors of ART adherence among HIV-monoinfected versus HIV/HCV-coinfecting individuals. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 954-962.	1.2	20
104	Perinatal outcomes in women living with HIV and receiving antiretroviral therapy: a systematic review and meta-analysis. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2022, 101, 168-182.	2.8	19
105	Effect of Gender and Calendar Year on Time to and Duration of Virologic Suppression Among Antiretroviral-Naïve HIV-Infected Individuals Initiating Combination Antiretroviral Therapy. <i>HIV Clinical Trials</i> , 2010, 11, 340-350.	2.0	18
106	Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV coinfecting patients in Canada. <i>Journal of the International AIDS Society</i> , 2018, 21, e25197.	3.0	18
107	Plea for multitargeted interventions for severe COVID-19. <i>Lancet Infectious Diseases</i> , 2020, 20, 1122-1123.	9.1	18
108	Predictive Value of HIV-1 Protease Genotype and Virtual Phenotype on the Virological Response to Lopinavir/Ritonavir-Containing Salvage Regimens. <i>Antiviral Therapy</i> , 2004, 9, 595-602.	1.0	18

#	ARTICLE	IF	CITATIONS
109	Salvage antiretroviral therapy in HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 81-90.	1.8	17
110	CD4+Cell Count Increase Predicts Clinical Benefits in Patients with Advanced HIV Disease and Persistent Viremia after 1 Year of Combination Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2005, 192, 1407-1411.	4.0	17
111	Comparison of Prognostic Importance of Latest CD4+ Cell Count and HIV RNA Levels in Patients with Advanced HIV Infection on Highly Active Antiretroviral Therapy. <i>HIV Clinical Trials</i> , 2005, 6, 127-135.	2.0	17
112	Which HIV patients should be screened for osteoporosis. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 268-276.	3.8	17
113	The Association Between HIV Disclosure Status and Perceived Barriers to Care Faced by Women Living with HIV in Latin America, China, Central/Eastern Europe, and Western Europe/Canada. <i>AIDS Patient Care and STDs</i> , 2016, 30, 435-444.	2.5	17
114	Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy. <i>Aids</i> , 2001, 15, 1581-1584.	2.2	17
115	Comparative Tolerability of Therapies for Cytomegalovirus Retinitis. <i>Drug Safety</i> , 1999, 21, 203-224.	3.2	16
116	Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2012, 26, 1789-1794.	2.2	16
117	Self-Reported Preconception Care of HIV-Positive Women of Reproductive Potential. <i>Journal of the International Association of Providers of AIDS Care</i> , 2014, 13, 424-433.	1.5	16
118	Critical Review. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 153-161.	2.1	16
119	Elevated Levels of Estradiol in Human Immunodeficiency Virus-Infected Pregnant Women on Protease Inhibitor-Based Regimens. <i>Clinical Infectious Diseases</i> , 2018, 66, 420-427.	5.8	16
120	Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. <i>International Journal of Drug Policy</i> , 2019, 65, 41-49.	3.3	16
121	Where Are You From?. <i>New England Journal of Medicine</i> , 2002, 346, 764-767.	27.0	15
122	Long-Term Follow-up of a Cohort of HIV-Infected Patients Who Discontinued Maintenance Therapy for Cytomegalovirus Retinitis. <i>HIV Clinical Trials</i> , 2006, 7, 1-9.	2.0	15
123	CMV Retinopathy in the Antiretroviral Therapy Era: Prevention, Diagnosis, and Management. <i>Current Infectious Disease Reports</i> , 2012, 14, 435-444.	3.0	15
124	Raltegravir as antiretroviral therapy in HIV/AIDS. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 395-405.	1.8	15
125	Backbones versus core agents in initial ART regimens: one game, two players. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 856-861.	3.0	15
126	Evaluation of the merifluor immunofluorescent assay for the detection of <i>Cryptosporidium</i> and <i>Giardia</i> in sodium acetate formalin-fixed stools. <i>Diagnostic Microbiology and Infectious Disease</i> , 1994, 19, 89-91.	1.8	14

#	ARTICLE	IF	CITATIONS
127	HIV-positive Women Living in the Metropolitan Toronto Area: Their Experiences and Perceptions Related to HIV Testing. <i>Canadian Journal of Public Health</i> , 1997, 88, 18-22.	2.3	14
128	A Prospective Randomized Controlled Trial of Structured Treatment Interruption in HIV-Infected Patients Failing Highly Active Antiretroviral Therapy (Canadian HIV Trials Network Study 164). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 45, 418-425.	2.1	14
129	Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries. <i>BMC Infectious Diseases</i> , 2010, 10, 40.	2.9	14
130	Comparison of Abacavir/Lamivudine and Tenofovir/Emtricitabine Among Treatment-Naive HIV-Infected Patients Initiating Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 38-46.	2.1	14
131	The Recombinant Hepatitis B Surface Antigen Vaccine in Persons With HIV: Is Seroconversion Sufficient for Long-term Protection?. <i>Journal of Infectious Diseases</i> , 2012, 205, 1534-1538.	4.0	14
132	In Vitro and In Situ Evaluation of pH-Dependence of Atazanavir Intestinal Permeability and Interactions with Acid-Reducing Agents. <i>Pharmaceutical Research</i> , 2014, 31, 2404-2419.	3.5	14
133	Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw050.	0.9	14
134	Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin. <i>Aids</i> , 2017, 31, 175-176.	2.2	13
135	Clinical Impact of Double Protease Inhibitor Boosting with Lopinavir/Ritonavir and Amprenavir as Part of Salvage Antiretroviral Therapy. <i>HIV Clinical Trials</i> , 2003, 4, 301-310.	2.0	12
136	Longitudinal Trends in Antiretroviral Use in a Cohort of Men and Women in Ontario, Canada. <i>AIDS Patient Care and STDs</i> , 2006, 20, 245-257.	2.5	12
137	Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfecting with HIV: a prospective cohort study. <i>CMAJ Open</i> , 2013, 1, E106-E114.	2.4	12
138	Herpes Simplex Virus Type 2 Coinfection Does Not Accelerate CD4 Count Decline in Untreated HIV Infection. <i>Clinical Infectious Diseases</i> , 2013, 57, 448-457.	5.8	12
139	A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 73, 531-539.	2.1	12
140	Novel imaging modalities for the comparison of bone microarchitecture among HIV+ patients with and without fractures: a pilot study. <i>HIV Clinical Trials</i> , 2017, 18, 28-38.	2.0	12
141	Medication nonadherence, multitablet regimens, and food insecurity are key experiences in the pathway to incomplete HIV suppression. <i>Aids</i> , 2018, 32, 1323-1332.	2.2	12
142	Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 985-998.	1.1	12
143	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1₂₀₀₉ and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2012, 13, 23-32.	2.0	12
144	Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring (summary of 2002 guidelines). <i>Cmaj</i> , 2003, 168, 1671-4.	2.0	12

#	ARTICLE	IF	CITATIONS
145	Reactivation and dissemination of blastomycosis complicating hodgkin's disease: A case report and review of the literature. <i>American Journal of Hematology</i> , 1993, 43, 129-132.	4.1	11
146	Treatment of HIV Infection in Pregnant Women. <i>Drugs</i> , 2004, 64, 471-488.	10.9	11
147	Recent Immigrants Show improved Clinical Outcomes at a Tertiary Care HIV Clinic. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2012, 23, 9-14.	1.9	11
148	Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial. <i>Pilot and Feasibility Studies</i> , 2016, 2, 49.	1.2	11
149	Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?. <i>Clinical Infectious Diseases</i> , 2021, 73, 468-477.	5.8	11
150	Can Structured Treatment Interruptions (STIs) Be Used as a Strategy to Decrease Total Drug Requirements and Toxicity in HIV Infection?. <i>Journal of the International Association of Providers of AIDS Care</i> , 2002, 1, 95-103.	1.2	10
151	A Randomized Clinical Trial Comparing Nelfinavir and Ritonavir in Patients with Advanced HIV Disease (CPCRA 042/CTN 102). <i>HIV Clinical Trials</i> , 2004, 5, 7-18.	2.0	10
152	Effectiveness of Step-Wise Intervention Plan for Managing Nelfinavir-Associated Diarrhea: A Pilot Study. <i>HIV Clinical Trials</i> , 2005, 6, 203-212.	2.0	10
153	Systematic Review of Strategies to Measure HIV-Related Diarrhea. <i>HIV Clinical Trials</i> , 2007, 8, 155-163.	2.0	10
154	Reassessment of enfuvirtide's role in the management of HIV-1 infection. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2349-2362.	1.8	10
155	A Prospective Study of Body Fat Redistribution, Lipid, and Glucose Parameters in HIV-Infected Patients Initiating Combination Antiretroviral Therapy. <i>HIV Clinical Trials</i> , 2008, 9, 314-323.	2.0	10
156	Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men. <i>Aids</i> , 2009, 23, 429-431.	2.2	10
157	Who Needs Direct-Acting Antivirals for HCV? Challenges Faced in Advancing HCV Therapy for HIV-HCV-Coinfected Individuals. <i>Antiviral Therapy</i> , 2013, 18, 717-721.	1.0	10
158	Short Communication: Effects of Age on Virologic Suppression and CD4 Cell Response in HIV-Positive Patients Initiating Combination Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1579-1583.	1.1	10
159	Micronutrient Deficiency and Treatment Adherence in a Randomized Controlled Trial of Micronutrient Supplementation in ART-Naïve Persons with HIV. <i>PLoS ONE</i> , 2014, 9, e85607.	2.5	10
160	Enhanced syphilis screening among HIV-positive men (ESSAHM): a study protocol for a clinic-randomized trial with stepped wedge design. <i>Implementation Science</i> , 2015, 11, 8.	6.9	10
161	Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 595-597.	2.0	10
162	Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz055.	0.9	10

#	ARTICLE	IF	CITATIONS
163	Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2008, 9, 73-82.	2.0	10
164	Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. <i>Aids</i> , 2007, 21, 2245-2248.	2.2	9
165	Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 13-28.	4.4	9
166	Management of Persons Infected with Human Immunodeficiency Virus Requiring Admission to the Intensive Care Unit. <i>Critical Care Clinics</i> , 2013, 29, 603-620.	2.6	9
167	Contraceptive options for HIV-positive women: making evidence-based, patient-centred decisions. <i>HIV Medicine</i> , 2015, 16, 329-336.	2.2	9
168	Responder Interferon Î» Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2016, 214, 80-86.	4.0	9
169	Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients. <i>Aids</i> , 2018, 32, 751-759.	2.2	9
170	Deciphering the serological response to syphilis treatment in men living with HIV. <i>Aids</i> , 2020, 34, 2089-2096.	2.2	9
171	Improvement of HIV-Specific Immunity in HIV-Infected Twins Treated with Highly Active Antiretroviral Therapy, Interleukin 2, and Syngeneic Adoptively Transferred Cells. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 887-900.	1.1	8
172	The role of lopinavir/ritonavir (Kaletra®) in the management of HIV infected adults. <i>Expert Review of Anti-Infective Therapy</i> , 2003, 1, 389-401.	4.4	8
173	Inclusion body myositis. <i>Aids</i> , 2003, 17, 1266-1267.	2.2	8
174	Canadian Consensus Guidelines for the Management of Cytomegalovirus Disease in HIV/AIDS. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2004, 15, 327-335.	1.9	8
175	Evaluation of Stool Frequency and Stool Form as Measures of HIV-Related Diarrhea. <i>HIV Clinical Trials</i> , 2007, 8, 421-428.	2.0	8
176	Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: A Multicenter Randomized Double-Blind Placebo-Controlled Trial. <i>HIV Clinical Trials</i> , 2014, 15, 161-175.	2.0	8
177	Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C Coinfected Persons. <i>Clinical Infectious Diseases</i> , 2016, 62, 242-249.	5.8	8
178	A cross-sectional population-based study of breast cancer screening among women with HIV in Ontario, Canada. <i>CMAJ Open</i> , 2017, 5, E673-E681.	2.4	8
179	Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine. <i>BMJ Open</i> , 2017, 7, e017391.	1.9	8
180	Increased CD4:CD8 ratio normalization with implementation of current ART management guidelines. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 729-737.	3.0	8

#	ARTICLE	IF	CITATIONS
181	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. <i>Trials</i> , 2021, 22, 224.	1.6	8
182	Lipodystrophy Severity Does Not Contribute to HAART Nonadherence. <i>AIDS and Behavior</i> , 2006, 10, 273-277.	2.7	7
183	Design and methods of the MAINTAIN study: A randomized controlled clinical trial of micronutrient and antioxidant supplementation in untreated HIV infection. <i>Contemporary Clinical Trials</i> , 2010, 31, 604-611.	1.8	7
184	Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial. <i>Mediators of Inflammation</i> , 2014, 2014, 1-10.	3.0	7
185	What's new for antiretroviral treatment in women with HIV. <i>Journal of Virus Eradication</i> , 2016, 2, 67-77.	0.5	7
186	Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients. <i>BMC Infectious Diseases</i> , 2017, 17, 266.	2.9	7
187	Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancer. <i>Aids</i> , 2018, 32, 2640-2642.	2.2	7
188	Brief Report: Persistence of Non-Vaccine Oncogenic HPV Genotypes in Quadrivalent HPV-Vaccinated Women Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 230-234.	2.1	7
189	Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada. <i>Trials</i> , 2020, 21, 647.	1.6	7
190	CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. <i>BMJ Open</i> , 2021, 11, e054208.	1.9	7
191	Is Chromium an Important Element in HIV-Positive Patients with Metabolic Abnormalities? An Hypothesis Generating Pilot Study. <i>Journal of the American College of Nutrition</i> , 2006, 25, 56-63.	1.8	6
192	The Effect of Dairy Product Ingestion on Human Immunodeficiency Virus-Related Diarrhea in a Sample of Predominantly Gay Men. <i>Archives of Internal Medicine</i> , 2006, 166, 1178.	3.8	6
193	An Estimate of the Proportion of Symptoms Reported in Self-Administered Questionnaires That Are Captured as Adverse Drug Events in an Observational Database. <i>HIV Clinical Trials</i> , 2007, 8, 311-319.	2.0	6
194	High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine. <i>Journal of Clinical Immunology</i> , 2014, 34, 655-662.	3.8	6
195	Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv059.	0.9	6
196	Herpes Simplex Virus Type 2 Serostatus Is Not Associated with Inflammatory or Metabolic Markers in Antiretroviral Therapy-Treated HIV. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 276-281.	1.1	6
197	Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfecting patients. <i>Aids</i> , 2016, 30, 1403-1311.	2.2	6
198	Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study. <i>BMC Infectious Diseases</i> , 2017, 17, 80.	2.9	6

#	ARTICLE	IF	CITATIONS
199	Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis. <i>Drug and Alcohol Dependence</i> , 2018, 185, 374-380.	3.2	6
200	Pilot study assessing the Rotterdam Healthy Aging Score in a cohort of HIV-positive adults in Toronto, Canada. <i>Aids</i> , 2020, 34, 859-867.	2.2	6
201	A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection. <i>PLoS ONE</i> , 2017, 12, e0176282.	2.5	6
202	Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. <i>International Journal of Drug Policy</i> , 2022, 103, 103627.	3.3	6
203	The Effect of Infection and Lag Screw Fixation on the Union of Membranous Bone Grafts in a Rabbit Model. <i>Plastic and Reconstructive Surgery</i> , 1994, 93, 574-581.	1.4	5
204	Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals. <i>Lancet, The</i> , 2004, 364, 1036-1037.	13.7	5
205	Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection – The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index. <i>PLoS ONE</i> , 2015, 10, e0129868.	2.5	5
206	Favourable IFNL3 Genotypes Are Associated with Spontaneous Clearance and Are Differentially Distributed in Aboriginals in Canadian HIV-Hepatitis C Co-Infected Individuals. <i>International Journal of Molecular Sciences</i> , 2015, 16, 6496-6512.	4.1	5
207	Injection Drug Use, Unemployment, and Severe Food Insecurity Among HIV-HCV Co-Infected Individuals: A Mediation Analysis. <i>AIDS and Behavior</i> , 2017, 21, 3496-3505.	2.7	5
208	The Use of Multistate Models to Examine Associations of Stress and Adherence With Transitions Among HIV Care States Observed in a Clinical HIV Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 303-310.	2.1	5
209	Exploring the impact of HIV infection and antiretroviral therapy on placenta morphology. <i>Placenta</i> , 2021, 104, 102-109.	1.5	5
210	The Effect of Infection and Lag Screw Fixation on Revascularization and New Bone Deposition in Membranous Bone Grafts in a Rabbit Model. <i>Plastic and Reconstructive Surgery</i> , 1996, 98, 338-345.	1.4	4
211	Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2001, 12, 20C-30C.	0.3	4
212	Rosiglitazone for HIV-1 lipodystrophy. <i>Lancet, The</i> , 2004, 363, 1828-1829.	13.7	4
213	Mild to Moderate Symptoms Do Not Correlate with Lactate Levels in HIV-Positive Patients on Nucleoside Reverse Transcriptase Inhibitors. <i>HIV Clinical Trials</i> , 2006, 7, 107-115.	2.0	4
214	Etravirine for HIV-1: Addressing the Limitations of the Nonnucleoside Reverse Transcriptase Inhibitor Class. <i>Journal of the International Association of Providers of AIDS Care</i> , 2009, 8, 354-363.	1.2	4
215	Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALAcyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial. <i>Trials</i> , 2010, 11, 113.	1.6	4
216	Missed Opportunities for Hepatocellular Carcinoma Screening in an HIV/Hepatitis C Virus-Coinfected Cohort. <i>Clinical Infectious Diseases</i> , 2013, 57, 1339-1342.	5.8	4

#	ARTICLE	IF	CITATIONS
217	A systematic review of the use of atazanavir in women infected with HIV type-1. <i>Antiviral Therapy</i> , 2014, 19, 293-307.	1.0	4
218	Effect of Intercurrent Infections and Vaccinations on Immune and Inflammatory Biomarkers Among Human Immunodeficiency Virus-Infected Adults on Suppressive Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv036.	0.9	4
219	Exploring the Factors Considered by People Living with HIV and Their Partners during Preconception. <i>Journal of the International Association of Providers of AIDS Care</i> , 2017, 16, 239-246.	1.5	4
220	Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks. <i>HIV/AIDS - Research and Palliative Care</i> , 2017, Volume 9, 51-61.	0.8	4
221	Activation and gut-homing of peripheral T cells in HIV immunologic non-responders despite long term viral suppression. <i>PLoS ONE</i> , 2021, 16, e0254149.	2.5	4
222	Cognitive remediation group therapy compared to mutual aid group therapy for people aging with HIV-associated neurocognitive disorder: randomized, controlled trial. <i>Social Work With Groups</i> , 2022, 45, 116-131.	0.5	4
223	Long-Term Predictive Value of a Single Cytomegalovirus (CMV) DNA PCR Assay for CMV Disease in Human Immunodeficiency Virus-Infected Patients. <i>Journal of Clinical Microbiology</i> , 1998, 36, 281-283.	3.9	4
224	Field Evaluation of the Merlin Immediate HIV-1 and -2 Test for Point-of-Care Detection of Human Immunodeficiency Virus Antibodies. <i>Clinical Infectious Diseases</i> , 2002, 34, 658-661.	5.8	3
225	Canadian Consensus Recommendations for the Optimal Use of Enfuvirtide in HIV/AIDS Patients. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2006, 17, 155-163.	1.9	3
226	Randomized Controlled Trial of Once-Daily Tenofovir, Lamivudine, and Lopinavir/Ritonavir Versus Remaining on the Same Regimen in Virologically Suppressed HIV-Infected Patients on Their First PI-Containing HAART Regimen. <i>HIV Clinical Trials</i> , 2007, 8, 259-268.	2.0	3
227	Review: Xpert MTB/RIF assay detects extrapulmonary TB in lymph nodes and CSF, but not pleural fluid. <i>Annals of Internal Medicine</i> , 2015, 162, JC11.	3.9	3
228	Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial. <i>PLoS ONE</i> , 2019, 14, e0221653.	2.5	3
229	Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV. <i>Vaccine</i> , 2020, 38, 3073-3078.	3.8	3
230	Prevalent and persistent oncogenic HPV types in a cohort of women living with HIV prior to HPV vaccination. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 150, 108-115.	2.3	3
231	Routinized Syphilis Screening Among Men Living With Human Immunodeficiency Virus: A Stepped Wedge Cluster Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2021, , .	5.8	3
232	Randomized, Blinded, Placebo-Controlled Trial of De Simone Formulation Probiotic During HIV-Associated Suboptimal CD4+ T Cell Recovery. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 199-207.	2.1	3
233	Vaginal microbiota associated with oncogenic HPV in a cohort of HPV-vaccinated women living with HIV. <i>International Journal of STD and AIDS</i> , 2022, 33, 847-855.	1.1	3
234	Combining protease inhibitors with new drug classes in treatment-experienced patients. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 647-652.	3.8	2

#	ARTICLE	IF	CITATIONS
235	First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approach. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 493-498.	3.8	2
236	Factors Associated With HIV-Positive Women Carrying Pregnancies to Term. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2010, 32, 756-762.	0.7	2
237	Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV-Infected Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2010, 21, 159-172.	1.9	2
238	Factors Associated With 30-Day Mortality Rate in Respiratory Infections Caused by <i>Streptococcus pneumoniae</i> . <i>Clinical Infectious Diseases</i> , 2018, 66, 1282-1285.	5.8	2
239	High retention in HIV care at a tertiary care centre in Toronto, Canada. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 246-254.	1.2	2
240	Heart Failure With Preserved Ejection Fraction in Women Living With HIV: Another Inflammatory Comorbidity?. <i>Journal of Infectious Diseases</i> , 2019, 221, 1219-1222.	4.0	2
241	Alendronate/Vitamin D for attenuating bone mineral density loss during antiretroviral initiation: a pilot randomized controlled trial. <i>HIV Research and Clinical Practice</i> , 2019, 20, 140-150.	1.1	2
242	Urinary symptoms and quality of life in women living with HIV: a cross-sectional study. <i>International Urogynecology Journal</i> , 2021, 32, 353-358.	1.4	2
243	Estimating an individual-level deprivation index for HIV/HCV coinfecting persons in Canada. <i>PLoS ONE</i> , 2021, 16, e0249836.	2.5	2
244	Patient perspectives on the implementation of routinised syphilis screening with HIV viral load testing: Qualitative process evaluation of the Enhanced Syphilis Screening Among HIV-positive Men trial. <i>BMC Health Services Research</i> , 2021, 21, 625.	2.2	2
245	Human herpesvirus 8 infection of the genital tract of HIV-seropositive and HIV-seronegative women at risk of sexually transmitted diseases. <i>Aids</i> , 2000, 14, 1073.	2.2	2
246	What's new for antiretroviral treatment in women with HIV. <i>Journal of Virus Eradication</i> , 2016, 2, 67-77.	0.5	2
247	The Dietary Inflammatory Index Is Not Associated With Gut Permeability or Biomarkers of Systemic Inflammation in HIV Immunologic Non-responders. <i>Frontiers in Nutrition</i> , 2021, 8, 736816.	3.7	2
248	Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 480-488.	3.0	1
249	Hepatitis C virus testing in a clinical <scp>HIV</scp> cohort in Ontario, Canada, 2000 to 2015. <i>Health Science Reports</i> , 2021, 4, e358.	1.5	1
250	Individualized therapy for the treatment-experienced patient. <i>Aids Reader</i> , 2003, 13, S11-5.	0.3	1
251	Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. <i>Dermatology and Therapy</i> , 2022, 12, 1073-1089.	3.0	1
252	Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population in Canada. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	1

#	ARTICLE	IF	CITATIONS
253	Alitretinoin. <i>American Journal of Clinical Dermatology</i> , 2000, 1, 315-316.	6.7	0
254	Valganciclovir. <i>Drugs</i> , 2001, 61, 1151-1152.	10.9	0
255	Organ Transplantation in HIV Infected Individuals: The Time Has Come - Should there Be Criteria?. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2006, 17, 8-10.	1.9	0
256	Response to Stegmann S, et al. [J. Clin. Virol. 47 (1) (2010) 79â€“81]. <i>Journal of Clinical Virology</i> , 2010, 47, 297-298.	3.1	0
257	Impact of Baseline Virologic, Immunologic, and Demographic Characteristics on Virologic Responses in the Gemini Study. <i>HIV Clinical Trials</i> , 2012, 13, 111-117.	2.0	0
258	Issues in resistance, adherence, and comparative efficacy of the single-tablet regimen combination of tenofovir, emtricitabine, and efavirenz in the management of HIV-1 infection. <i>Virus Adaptation and Treatment</i> , 0, , 51.	1.5	0
259	The clinical cost of delays in switching therapy. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2007, 18 Suppl A, 5A-7A.	1.9	0
260	Structured interruption of treatment hastened disease progression in multidrug-resistant HIV. <i>ACP Journal Club</i> , 2004, 140, 64.	0.1	0
261	Neighbourhood-level material deprivation and response to combination antiretroviral therapy in the Canadian Observational Cohort (CANOC): a longitudinal cohort study. <i>CMAJ Open</i> , 2022, 10, E183-E189.	2.4	0
262	Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIVâ€“HCV co-infected population in Canada. <i>Antiviral Therapy</i> , 2022, 27, 135965352110676.	1.0	0
263	Structured interruption of treatment hastened disease progression in multidrug-resistant HIV. <i>ACP Journal Club</i> , 2004, 140, 64.	0.1	0
264	A randomized control trial of high-dose micronutrient-antioxidant supplementation in healthy persons with untreated HIV infection. <i>PLoS ONE</i> , 2022, 17, e0270590.	2.5	0